Phio Pharmaceuticals (PHIO) Non-Current Assets (2011 - 2026)
Phio Pharmaceuticals' (PHIO) quarterly Non-Current Assets came in at $10000.0 in Q1 2026, up 150.0% YoY from $4000.0 in Q1 2025, and down 9.09% on a QoQ basis from $11000.0 in Q4 2025.
Phio Pharmaceuticals (PHIO) Non-Current Assets (2011 - 2026) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 16 years of Non-Current Assets data on file, last reported at $10000.0 in Q1 2026.
- Quarterly Non-Current Assets rose 150.0% year-over-year to $10000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40000.0 (up 263.64% YoY) and the FY2025 annual result came in at $11000.0, up 450.0% from the prior year.
- Non-Current Assets fell to $10000.0 in Q1 2026, from $11000.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $495000.0 in Q1 2022 to a low of -$1.1 million in Q1 2024.
- A 5-year average of $87705.9 and a median of $12000.0 in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets tumbled 466.34% — and 2025, when it soared 1100.0%.
- Tracing PHIO's Non-Current Assets over 5 years: stood at $368000.0 in 2022, then plunged by 88.59% to $42000.0 in 2023, then slumped by 95.24% to $2000.0 in 2024, then soared by 450.0% to $11000.0 in 2025, then dropped by 9.09% to $10000.0 in 2026.
- The last three Non-Current Assets figures came in at $10000.0 (Q1 2026), $11000.0 (Q4 2025), and $12000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - | 9,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9,000.00 |
| Mar 31, 2026 | 10,000.00 |
| Dec 31, 2025 | 11,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Jun 30, 2025 | 7,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Mar 31, 2024 | -1.11 Mn |
| Dec 31, 2023 | 42,000.00 |
| Sep 30, 2023 | 211,000.00 |
| Jun 30, 2023 | 261,000.00 |
| Mar 31, 2023 | 303,000.00 |
| Dec 31, 2022 | 368,000.00 |
| Sep 30, 2022 | 414,000.00 |
| Jun 30, 2022 | 456,000.00 |
| Mar 31, 2022 | 495,000.00 |
| Dec 31, 2021 | 443,000.00 |
| Sep 30, 2021 | 493,000.00 |